Final Height in Girls with Turner Syndrome after Long-Term Growth Hormone Treatment in Three Dosages and Low Dose Estrogens

Author:

van Pareren Yvonne K.1,de Muinck Keizer-Schrama Sabine M. P. F.1,Stijnen Theo2,Sas Theo C. J.1,Jansen Maarten3,Otten Barto J.4,Hoorweg-Nijman J. J. Gera5,Vulsma Thomas6,Stokvis-Brantsma Wilhelmina H.7,Rouwé Catrienus W.8,Reeser H. Maarten9,Gerver Willem-Jan10,Gosen Jos J.11,Rongen-Westerlaken Ciska12,Drop Stenvert L. S.1

Affiliation:

1. Department of Pediatrics, Division of Endocrinology, Erasmus University MC/Sophia Children’s Hospital (Y.K.v.P., S.M.P.F.d.M.K.-S., T.C.J.S., S.L.S.D.), 3015 GJ Rotterdam, The Netherlands

2. Department of Epidemiology and Biostatistics, Erasmus University MC (T.S.), 3015 GJ Rotterdam, The Netherlands

3. Wilhelmina Children’s Hospital (M.J.), 3584 EA Utrecht, The Netherlands

4. Sint Radboud University Hospital (B.J.O.), 6523 GA Nijmegen, The Netherlands

5. Free University Hospital (J.J.G.H.-N.), 1081 HV Amsterdam, The Netherlands

6. Academic Medical Center/Emma Children’s Hospital (T.V.), 1105 AZ Amsterdam, The Netherlands

7. Medical University Center (W.H.S.), 2333 ZA Leiden, The Netherlands

8. Beatrix Children’s Hospital (C.W.R.), 9713 GZ Groningen, The Netherlands

9. Juliana Children’s Hospital (H.M.R.), 2566 MJ The Hague, The Netherlands

10. Academic Hospital (W.J.G.), 6229 HX Maastricht, The Netherlands

11. Rijnland Hospital (J.J.G.), 2353 GA Leiderdorp, The Netherlands

12. Canisius-Wilhelmina Hospital (C.R-W.), 6532 SZ Nijmegen, The Netherlands

Abstract

Although GH treatment for short stature in Turner syndrome is an accepted treatment in many countries, which GH dosage to use and which age to start puberty induction are issues of debate. This study shows final height (FH) in 60 girls with Turner syndrome treated in a randomized dose-response trial, combining GH treatment with low dose estrogens at a relatively young age. Girls were randomly assigned to group A (4 IU/m2·d; ∼0.045 mg/kg/d), group B (first year, 4 IU/m2·d; thereafter 6 IU/m2·d), or group C (first year, 4 IU/m2·d; second year, 6 IU/m2·d; thereafter, 8 IU/m2·d). After a minimum of 4 yr of GH treatment, at a mean age of 12.7 ± 0.7 yr, low dose micronized 17β-estradiol was given orally. After a mean duration of GH treatment of 8.6 ± 1.9 yr, FH was reached at a mean age of 15.8 ± 0.9 yr. FH, expressed in centimeters or sd score, was 157.6 ± 6.5 or −1.6 ± 1.0 in group A, 162.9 ± 6.1 or −0.7 ± 1.0 in group B, and 163.6 ± 6.0 or −0.6 ± 1.0 in group C. The difference in FH in centimeters, corrected for height sd score and age at start of treatment, was significant between groups A and B [regression coefficient, 4.1; 95% confidence interval (CI), 1.4, 6.9; P < 0.01], and groups A and C (coefficient, 5.0; 95% CI, 2.3, 7.7; P < 0.001), but not between groups B and C (coefficient, 0.9; 95% CI, −1.8, 3.6). Fifty of the 60 girls (83%) had reached a normal FH (FH sd score, more than −2). After starting estrogen treatment, the decrease in height velocity (HV) changed significantly to a stable HV, without affecting bone maturation (change in bone age/change in chronological age). The following variables contributed significantly to predicting FH sd score: GH dose, height sd score (ref. normal girls), chronological age at start of treatment, and HV in the first year of GH treatment. GH treatment was well tolerated. In conclusion, GH treatment leads to a normalization of FH in most girls, even when puberty is induced at a normal pubertal age. The optimal GH dosage depends on height and age at the start of treatment and first year HV.

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference32 articles.

1. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome.;Rao;Nat Genet,1997

2. Growth hormone secretion in patients with Turner’s syndrome as determined by time series analysis.;Wit;Acta Endocrinol (Copenh),1992

3. Growth hormone, somatomedin levels and growth regulation in Turner’s syndrome.;Ranke;Acta Endocrinol (Copenh),1987

4. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial.;Sas;J Clin Endocrinol Metab,1999

5. Hormonal changes during development in Turner’s syndrome;Van Vliet;Acta Paediatr Scand,1988

Cited by 198 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3